Defeat Cancer by Detecting it Early
EarlyDiagnostics (EarlyDx) is devoted to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine.
About
Big Data for Better Diagnosis
We have developed a blood test, CancerRadar, which is highly accurate and sensitive in detecting and locating cancer. In addition, we developed a One-Stop Shop bioinformatics solution, EarlyDx-Cloud, to help many diagnostic companies offer liquid biopsy tests for cancer detection, therapy selection, and treatment monitoring.
how it works
The Technology behind Cancer Detection
Discover our experimental and computational innovations.
cfMethyl-seq
cfMethyl-seq technology – a novel NGS solution to profile the cfDNA methylome.
cfSNV
A novel computational tool to accurately call mutations directly from blood.
cfTrack
Non-invasive monitoring of cancer MRD, Recurrence, and Evolution.
EarlyDx-Cloud
A “One-Stop Shop” bioinformatics solution for liquid biopsy.
Publications
Our technologies are empowered by Innovation.
Our Team
Our Experts Are Waiting For You
We bring the right people together to challenge established thinking and drive transformation.
Latest News
Read the latest news and blog posts from EarlyDx.
June 2022
EarlyDx announced appointment of Guanghui Hu as co-CEO.
May 2022
EarlyDx published cfTrack: Non-invasive monitoring of cancer MRD, Recurrence, and Evolution in Clinical Cancer Research.
Sep 2021
EarlyDx Awarded an NIH SBIR Phase I Contract for Cloud Platform Development.